These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36349773)

  • 1. Active Surveillance in Prostate Cancer: Current and Potentially Emerging Biomarkers for Patient Selection Criteria.
    Sotomayor PC; Aguilar JC; Mujica K; Zuñiga A; Godoy AS; Smith GJ; Mohler JL; Vitagliano G; San Francisco IF
    Urol Int; 2022; 106(12):1201-1213. PubMed ID: 36349773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-risk Prostate Cancer: Identification, Management, and Outcomes.
    Moschini M; Carroll PR; Eggener SE; Epstein JI; Graefen M; Montironi R; Parker C
    Eur Urol; 2017 Aug; 72(2):238-249. PubMed ID: 28318726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
    Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
    Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
    Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review.
    van den Bergh RC; Ahmed HU; Bangma CH; Cooperberg MR; Villers A; Parker CC
    Eur Urol; 2014 Jun; 65(6):1023-31. PubMed ID: 24491309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical prostatectomy versus deferred treatment for localised prostate cancer.
    Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Narrative Overview of Active Surveillance for Clinically Localised Prostate Cancer.
    Bates AS; Kostakopoulos N; Ayers J; Jameson M; Todd J; Lukha R; Cymes W; Chasapi D; Brown N; Bhattacharya Y; Paterson C; Lam TBL
    Semin Oncol Nurs; 2020 Aug; 36(4):151045. PubMed ID: 32703714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Jan; 65(1):124-37. PubMed ID: 24207135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active surveillance for prostate cancer: a systematic review of the literature.
    Dall'Era MA; Albertsen PC; Bangma C; Carroll PR; Carter HB; Cooperberg MR; Freedland SJ; Klotz LH; Parker C; Soloway MS
    Eur Urol; 2012 Dec; 62(6):976-83. PubMed ID: 22698574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evidence review of active surveillance in men with localized prostate cancer.
    Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
    Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
    Heidenreich A; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Mottet N; Schmid HP; van der Kwast T; Wiegel T; Zattoni F;
    Eur Urol; 2011 Jan; 59(1):61-71. PubMed ID: 21056534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of active surveillance in prostate cancer.
    Chung MS; Lee SH
    Investig Clin Urol; 2016 Jan; 57(1):14-20. PubMed ID: 26966722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of curative treatment for prostate cancer: a systematic review.
    van den Bergh RC; Albertsen PC; Bangma CH; Freedland SJ; Graefen M; Vickers A; van der Poel HG
    Eur Urol; 2013 Aug; 64(2):204-15. PubMed ID: 23453419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment?
    Huland H; Graefen M
    Eur Urol; 2015 Aug; 68(2):175-8. PubMed ID: 25736732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the selection of patients with prostate cancer for active surveillance.
    Liu JL; Patel HD; Haney NM; Epstein JI; Partin AW
    Nat Rev Urol; 2021 Apr; 18(4):197-208. PubMed ID: 33623103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Markers in Prostate Cancer Decision Making.
    Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
    Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using Competing Risk of Mortality to Inform the Transition from Prostate Cancer Active Surveillance to Watchful Waiting.
    Huang MM; Alam R; Gabrielson AT; Su ZT; Kassiri B; Fletcher SA; Biles MJ; Patel HD; Pavlovich CP; Schwen ZR
    Eur Urol Focus; 2022 Sep; 8(5):1141-1150. PubMed ID: 34344628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active surveillance for prostate cancer: past, present and future.
    Singer EA; Kaushal A; Turkbey B; Couvillon A; Pinto PA; Parnes HL
    Curr Opin Oncol; 2012 May; 24(3):243-50. PubMed ID: 22450149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.